Blood and Marrow Transplant Group of Georgia

Clinical Trials
Open BMT Studies - Updated December 15, 2011

NSH 721 – NMDP Recipient Consent for Participation in Registry, Research Database, and Research Sample Repository
NSH 886 – A Randomized, double-blind, placebo-controlled Phase III study of SGN-35 (brentuximab vedotin) and BSC versus placebo and BSC in the treatment of patients at high risk for residual HL following ASCT
NSH 887 – A Multicenter, Randomized, Double Blind, Phase III Trial Evaluating Corticosteroids with MMF vs. Corticosteroids with Placebo as Initial Systemic Treatment of Acute GVHD
NSH 888 – The Impact of Hematopoietic Stem Cell Transplantation on Primary Caregiver Level of Burden and Distress
NSH 890 – Evaluation of Lenalidomide as Maintenance Therapy after Allogeneic Hematopoietic Stem Cell Transplantation for High-Risk Multiple Myeloma
NSH 893 – Phase II Trial Evaluating the Safety and Efficacy of Rituximab as Primary Treatment for Extensive Chronic Graft Versus Host Disease
NSH 894 – A Trial of Single Autologous Transplant with or without Consolidation Therapy versus Tandem Autologous Transplant with Lenalidomide Maintenance for Patients with Multiple Myeloma; BMT CTN 0702
NSH 898 – A Randomised Phase III Study of Elacytarabine vs. Investigator’s Choice in Patients with Late Stage Acute Myeloid Leukaemia
NSH 900 – BMT CTN 0804/CALGB 100701 Phase II Study of Reduced-Intensity Allogeneic Stem Cell Transplant for High-Risk Chronic Lymphocytic Leukemia (CLL) (available now through CTN)
NSH 909 – A Prospective Assessment of the Diagnostic Utility of Emerging Laboratory Assessments Used in Conjunction with Fiberoptic Bronchoscopy (FOB) in Hematopoietic Stem Cell Transplant (HSCT) and Leukemia Patients with Acute Respiratory Symptoms and Pulmonary Infiltrates
NSH 911 – A Phase II Trial of Post-Transplant Cyclophosphamide for Graft Versus Host Disease (GVHD) Prophylaxis Following Reduced Intensity Unrelated Donor Allogeneic Peripheral Blood Stem Cell Transplantation
NSH 916 – BMT CTN 0803 High Dose Chemotherapy with Autologous Stem Cell Rescue for Aggressive B Cell Lymphoma and Hodgkin Lymphoma in HIV-infected Patients
NSH 922 – A Phase II Trial of Total Body Irradiation-Based Myeloablative Conditioning and Transplantation of Partially HLA-Mismatched Peripheral Blood Stem Cells for Patients with Hematologic Malignancies
NSH 923 –A Phase III randomized Study of Oral Sapacitabine in Elderly Patient with newly Diagnosed AML
NSH 936 – BMT CTN 0301 Fludarabine-based Conditioning for Allogeneic Marrow Transplantation From HLA-compatible Unrelated Donors in Severe Aplastic Anemia
NSH 943 – A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs) for transplantation in pediatric and adult patients with hematologic malignancies and other indications
NSH 958 – BMT CTN 0902 – A Phase III Randomized, Multicenter Trial Testing Whether Exercise or Stress Management Improves Functional Status and Symptoms of Autologous and Allogeneic Recipients

BMT- STANDARD OF CARE PREPARATIVE REGIMENS

Myeloablative
SC-100 (old 408) Auto/Allo/MUD	Cy/TBI	Cy 60 mg/kg IV q24h x 2 doses Days -6 & -5	TBI 150 cGy BID x 8 fractions Days -4 to -1
SC-101-A (old 408) Mismatched MUD	Cy/TBI/rATG	Cy 60 mg/kg IV q24h x 2 doses Days -6 & -5	TBI 150 cGy BID x 8 fractions Days -4 to -1	rATG 2 mg/kg IV q24h x 3 doses Days -3, -2, & -1
SC-102 ALL (old 408) Auto/Allo/MUD	Etopophos/TBI	Etopophos 60 mg/kg IV IV x 1 dose Day -4	TBI 150 cGy BID x 8 fractions Days -4 to -1
SC-102-A ALL (old 408) Mismatched MUD	Etophphos/TBI/rATG	Etopophos 60 mg/kg IV x 1 dose Day -4	TBI 150 cGy BID x 8 fractions Days -4 to -1	rATG 2 mg/kg IV q24h x 3 doses Days -3, -2, & -1
SC-103 Auto/Allo/MUD	PO BU/CY	Bu 1 mg/kg test dose PO day -9 Then Q6h x 15 doses Days -7 to -3	Cy 60 mg/kg IV q24h x 2 doses Days -3 & -2
SC-103-I Auto/Allo/MUD	IV Bu/CY	Bu 0.8 mg/kg test dose IV day -7 Then q6h x 15 doses Days -7 to -3	Cy 60 mg/kg IV q24h x 2 doses Days -3 & -2
SC-103-T (Targeted Bu) Auto/Allo/MUD	PO Bu/CY	Bu 1 mg/kg test dose PO day -9 Then Q6h x 15 doses Days -7 to -3 Targeted Measured Conc=900 umol/L per dose	Cy 60 mg/kg IV q24h x 2 doses Days -3 & -2
SC-104 Auto/Allo	PO Bu/Cy/ VP-16	Bu 1 mg/kg test dose PO day -10 Then Q6h x 15 doses Days -8 to -4	Cy 60 mg/kg IV q24h x 2 doses Days -3 & -2	VP-16 10 mg /kg IV q24h x 3 doses Days -4, -3 & -2
SC-104-I Auto/Allo	IV Bu/Cy/VP-16	Bu 0.8 mg/kg test dose IV day -9 Then q6h x 15 doses Days -8 to -4	Cy 60 mg/kg IV q24h x 2 doses Days -3 & -2	VP-16 10 mg /kg IV q24h x 3 doses Days -4, -3 & -2
SC-105 Auto	PO Bu/ Cy/Mel	Bu 1 mg/kg test dose PO day -9 Then Q6h x 15 doses Days -7 to -3	Cy 60 mg/kg IV q24h x 2 doses Days -3 & -2	Mel 90mg/m2 IV X 1 dose Day -1
SC-106-S Single auto	Mel	Mel 200mg/m2 IV Day -1
SC-106-R Reduced Mel Auto	Mel	Mel 140mg/m2 IV Day-1
SC-106-T-1 (old 719) Tandem Auto/Auto	Mel/Mel	Transplant #1 Mel 200mg/m2 IV X 1 dose Day -1	Transplant #2 Mel 200mg/m2 IV X 1 dose Day -1
SC-106-T-2 Tandem- allo regimen (given following Mel auto) (old 719)	Mel/TBI	Transplant #1 Mel 200mg/m2 IV X 1 dose Day -1	Transplant #2 TBI 200 cGy Day 0
SC-107 Auto	BEAM	BCNU 150 mg/m2 IV q24h x 2 doses Days -6 & -5 Mel 140 mg/m2 IV X 1 dose Day -2	VP-16 200 mg/m2 IV q24h x 4 doses Days -5 to -2	AraC 200 mg/m2 IV q12h x 8 doses Days -5 to -2
SC-108 Auto	STAMP V	Cy 1500 mg/m2 IV CI Q24h x 4 doses Days – 7 to -4	Thiotepa 125 mg/m2 IVCI q24h x 4 doses Days – 7 to -4	Carbo 200 mg/m2 IV CI q24h x 4 doses Days – 7 to -4
SC-109 Auto	Carbo/VP-16	Carbo 700 mg/m2 IV q24h X 3 doses Days -6 to -4	VP-16 750 mg/m2 IV q24h x 3 doses Days -6 to -4
SC-112 Allo/MUD	Flu/ PO Bu	Flu 40 mg/m2 IV Q24h x 4 doses Days -6 to -3	Bu 1 mg/kg test dose PO day -9 Then Q6h x 15 doses Days -7 to -3
SC-112-I Allo/MUD	Flu/IV Bu	Flu 40 mg/m2 IV Q24h x 4 doses Days -6 to -3	Bu 130 mg/m2 IV Q24h x 4 doses Days -6 to -3
SC-113 (high dose ICE) Auto	Ifos/VP-16/Carbo	Ifos 3000 mg/m2 IV Q24h x 4 doses Days -6 to -3	VP-16 200 mg/m2 IV Q12h x 6 doses Days -6 to -4	Carbo 300 mg/m2 IV Q24h x 4 doses Days-6 to -3
SC-114 (old 718/765) Refractory B Cell Lymphoma Auto	Etopophos/BCNU/Cy/ Rituxan	Etopophos 60 mg/kg IV IV x 1 dose Day -4	BCNU 15 mg/kg (max 550 mg/m2) IV x 1 dose Days -6		Cy 100 mg/kg IV X 1 dose day -2
SC-114 (old 718/765) Refractory B Cell Lymphoma Auto	Post Transplant Therapy at MD Discretion (old 765): Rituxan 375 mg/m2 IV days 42, 49, 56, and 63 Post Transplant Therapy at MD Discretion (old 718): Rituxan 375 mg/m2 IV days 1,8,15,22 x 5 cycles post transplant beginning day 45 then 6, 12, 18 & 24 months post transplant GM-CSF250 mcg/m2 SQ daily starts 3 days prior to first dose of rituximab and continues until the 7th day after last dose of each rituximab series.
SC-115 High-Risk MM Auto	Mel/Dex/Vel	Mel 200 mg/m2 IV x 1 dose day -1	Dex 20 mg PO x 4 doses Days -4 through -1		Vel 1.3 mg/m2 IV x 2 doses Days -4 & -1
SC-116 High-Risk MM Auto	Bu/Mel/Vel	Bu 0.8mg/kg test dose IV d-8 Then Q24h x 4 doses Days -6 through -3 Targeted Measured Conc=5000 umol/L per dose	Mel 140 mg/m2 IV x 1 dose -2		Vel 1.3 mg/m2 IV x 1 dose Day -1
Reduced Intensity
SC-203 Allo/MUD	Flu/Mel/Campath	Flu 30 mg/m2 IV q24h x 5 doses Days -7 to -3	Mel 140 mg/m2 IV X 1 dose Day -2	Campath 20 mg IV Q24h x 5 doses Days -8 to -4
SC-204 Allo/MUD	Flu/Mel	Flu 25 mg/m2 IV q24h x 5 doses Days -6 to -2	Mel 90 mg/m2 IV q24h X 2 doses Day -2 & -1
SC-205 Allo/MUD	Flu/Mel	Flu 30 mg/m2 IV q24h x 4 doses Days -5 to -2	Mel 140 mg/m2 IV X 1 dose Day -1
SC-206 (old 801) Allo/MUD	Flu/Mel/rATG	Flu 30 mg/m2 IV q24h x 5 doses Days -7 to -3	Mel 140 mg/m2 IV Day -2	rATG IV 1 mg/kg day -4 2.5 mg/kg days -3 & -2
SC-207 (Old NSH 807 w/o rATG) Allo	Flu/Bu/Cy	Flu 30 mg/m2 IV q24h x 5 doses Days -7 to -3 Cy 1.5 g/m2 IV day -2	Bu 130 mg/m2 IV q24h x 2 doses Days -4 & -3
SC-208 PBSC only AML, CML, MDS, MPS, AML (old 756-1) MUD	Flu/PO Bu/ Campath	Flu 40 mg/m2 IV q24h x 4 doses Days -6 to -3	Bu 1 mg/kg test dose PO day -9 Then Q6h x 15 doses Days -7 to -3	Campath SC 3 mg day -11 10 mg day -10 30 mg day -9
	GVHD prophylaxis: FK day -1 through day 60 (goal level 10-20) then taper according to T cell chimerism. If ³50% taper over 6 months; if <50% initiate DLI until Chimerism ³50%, then taper over 4 weeks. MTX 5 mg/m2 days +1, +3, & +6
SC-208-I PBSC only AML, CML, MDS, MPS, ALL (old 756-2) MUD	Flu/IV Bu/Campath	Flu 40 mg/m2 IV q24h x 4 doses Days -6 to -3	Bu 130 mg/m2 IV q24h x 4 doses Days -6 to -3	Campath SC 3 mg day -11 10 mg day -10 30 mg day -9
	GVHD prophylaxis: FK day -1 through day 60 (goal level 10-20) then taper according to T cell chimerism. If ³50% taper over 6 months; if <50% initiate DLI until Chimerism ³50%, then taper over 4 weeks. MTX 5 mg/m2 days +1, +3, & +6
SC-209 (Allo AA) Bone Marrow	Cy/ATGAM	Cy 50 mg/kg IV q24 x 4 doses Days -5 through -2	AGAM 30 mg/kg IV q24h x 3 doses Days -4 through -2
SC-210 (MUD AA) Bone Marrow	Cy/ATGAM +TBI	Cy 50 mg/kg IV q24 x 4 doses Days -5 through -2	AGAM 30 mg/kg IV q24h x 3 doses Days -4 through -2	TBI 200 cGy Day -1

Non-Myeloablative
SC-301 Allo	Flu/Cy	Flu 30 mg/m2 IV q24h x 3 doses Days -5 to -3	Cy 750 mg/m2 IV Q24h x 3 doses Days -5 to -3
SC-301-R (Rituxan CD 20+) Allo	Flu/Cy/Rituxan	Flu 30 mg/m2 IV q24h x 3 doses Days -5 to -3	Cy 750 mg/m2 IV Q24h x 3 doses Days -5 to -3	Rituxan 375 mg/m2 IV Days -13, -6, +1, & +8
SC-301-C PBSC only CLL, NHL, HD (old 756-3) MUD	Flu/Cy/Campath	Flu 30 mg/m2 IV q24h x 3 doses Days -5 t o -3	Cy 750 mg/m2 IV q24h x 3 doses Days -5 to -3	Campath SC 3 mg day -11 10 mg day -10 30 mg day -9
SC-301-C PBSC only CLL, NHL, HD (old 756-3) MUD	GVHD prophylaxis: FK day -1 through day 60 (goal level 10-20) then taper according to T cell chimerism. If ³50% taper over 6 months; if <50% initiate DLI until Chimerism ³50%, then taper over 4 weeks. MTX 5 mg/m2 days +1, +3, & +6
SC-301-CR PBSC only CLL, NHL, HD) (old 756-4) MUD	Flu/Cy/Campath/ Rituxan	Flu 30 mg/m2 IV q24h x 3 doses Days -5 t o -3 Rituxan 375 mg/m2 IV Day -13	Cy 750 mg/m2 IV q24h x 3 doses Days -5 to -3 Rituxan 1000 mg/m2 IV Day -6, +1, +8	Campath SC 3 mg day -11 10 mg day -10 30 mg day -9
SC-301-CR PBSC only CLL, NHL, HD) (old 756-4) MUD	GVHD prophylaxis: FK day -1 through day 60 (goal level 10-20) then taper according to T cell chimerism. If ³50% taper over 6 months; if <50% initiate DLI until Chimerism ³50%, then taper over 4 weeks. MTX 5 mg/m2 days +1, +3, & +6
SC-302 BM only (old NSH 747) Haplo	Flu/Cy/TBI	Flu 30 mg/m2 IV q24h x 5 doses Days -6 to -2	Cy 14.5 mg/kg IV Day -6 & -5 Cy 50 mg/kg IV Day +3 & +4	TBI 200 cGy Day -1
SC-302 BM only (old NSH 747) Haplo	GVHD prophylaxis: FK day +5 until day 180 (goal 5-15) + MMF day +5 through day +35
SC-303 cord	Flu/Cy/TBI	Flu 40 mg/m2 IV q24h x 5 doses Days -6 to -2	Cy 50 mg/kg IV X 1 dose Day -6	TBI 200 cGy Day-1
SC-303-E cord	Flu/Cy/TBI + EQUINE ATG	Flu 40 mg/m2 IV q24h x 5 doses Days -6 to -2	Cy 50 mg/kg IV X 1 dose Day -6	TBI 200 cGy Day-1 Equine ATG 15mg/kg IV Q12h x 6 doses Days -3 to -1
SC-304 Allo/MUD	Flu/Cy	Flu 25 mg/m2 IV q24h x 5 doses Days -5 to -1	Cy 60 mg/kg IV Q24h x 2 doses Days -7 and -6
SC-304R Allo/MUD	Flu/Cy/Rituxan	Flu 25 mg/m2 IV q24h x 5 doses Days -5 to -1	Cy 60 mg/kg IV Q24h x 2 doses Days -7 and -6	Rituxan 375 mg/m2 IV Days -13, -6, +1, & +8
SC-305 All/Mud	Flu/TBI	Flu 30 mg/m2 IV Q24h x 3 doses Days -4 to -2	TBI 200 cGy Day 0
SC-305 All/Mud	GVHD prophylaxis: FK (begins day -3) + MMF day 0 (following SCT) through day 40 then taper over 56 days

Leukemia Regimen List - December 15, 2011

AML
Induction

#	Regimen
AML I-101	Time Sequential Ara-C 667mg/m2 Ida 12mg/m2 VP-16 100mg/m2 Therapy (TST) Day 1-3 Day 1-3 Day 8-10 (Age<60)
AML I-102	Time Sequential Ara-C 667mg/m2 Ida 8mg/m2 VP-16 100mg/m2 Therapy (TST) Day 1-3 Day 1-3 Day 8-10 (Age>60)
AML I-103	FLAG Flu 25mg/m2 Ara-C 2000mg/m2 Neupogen 5mcg/kg SC starting Day 1-5 Day 1-5 Day 0 until count recovery
AML I-104	FLAG-Ida Flu 30mg/m2 Ara-C 2000mg/m2 Ida 10mg/m2 Day 1-5 Day 1-5 Day 1-3 Neupogen 5mcg/kg SC starting Day 0 until count recovery
AML I-105	7+3 (200mg/m2) Ara-C 200mg/m2 Ida 12mg/m2 Day 1-7 Day 1-3
AML I-106	7+3 (100mg/m2) Ara-C 100mg/m2 Ida 12mg/m2 Day 1-7 Day 1-3
AML I-107	SC Ara-C Ara-C 10mg/m2 BID Day 1-21
AML I-108	Vidaza Vidaza 75mg/m2 SC or IV X 7 days Monday-Friday
AML I-109	Vidaza/VPA Vidaza 75mg/m2 SC or IV VPA 5mg/kg PO TID Day 1-7 Starting day 1
AML I-110	Vidaza Vidaza 75mg/m2 SC or IV Day 1-5
AML I-111	Mito/VP-16 Mito 10mg/m2 VP-16 100mg/m2 Day 1-5 Day 1-5
AML I-112	Clofarabine Clofarabine 30mg/m2 Day 1-5
AML I -113	Clofarabine/Ara-C Ara-C 1000mg/m2 Clofarabine 40mg/m2 Induction #1 Day 1 – 5 Day 2 - 6
AML I -114	Dacogen Dacogen 20mg/m2 Day 1-5
AML I -115	Dacogen Dacogen 20mg/m2 (10 day) Day 1-10

Refractory/Relapse/Reinduction

#	Regimen
AML R-101	HAM Ara-C 3000mg/m2 Mito 10mg/m2 (Age<50) BID Day 1-6 Day 7-9
AML R-102	HAM Ara-C 2000mg/m2 Mito 10mg/m2 (Age>50) BID Day 1-6 Day 7-9
AML R-103	Mito/VP-16 Mito 10mg/m2 VP-16 100mg/m2 Day 1-5 Day 1-5
AML R-104	VP-16/Cy VP-16 3600mg/m2 Cy 50mg/kg Day 1 Day2-5
AML R-105	MIDAM Ara-C 1000mg/m2 Mito 12mg/m2 Mylotarg 9mg/m2 BID Day 1-5 Day 1-3 Day 4
AML R-106	Mylotarg Mylotarg 9mg/m2 Day 1 and 15
AML R-107	FLAG Flu 25mg/m2 Ara-C 2000mg/m2 Neupogen 5mcg/kg SC starting Day 1-5 Day 1-5 Day 0 until count recovery
AML R-108	FLAG-Ida Flu 30mg/m2 Ara-C 2000mg/m2 Ida 10mg/m2 Day 1-5 Day 1-5 Day 1-3 Neupogen 5mcg/kg SC starting Day 0 until count recovery
AML R-109	FLAG-Ida Flu 25mg/m2 Ara-C 2000mg/m2 Ida 12mg/m2 Mylotarg Day 1-5 Day 1-5 Day 1-5 Mylotarg 9mg/m2 Neupogen 5mcg/kg SC starting Day 8 Day +1 until count recovery
AML R-110	Time Sequential Ara-C 667mg/m2 Mito 40mg/m2 Bevacizumab 10mg/kg Therapy with Day 1-3 Day 4 Day 8 bevacizumab
AML R-111	Vidaza Vidaza 75mg/m2 SC or IV X 7 days Monday-Friday
AML R-112	Vidaza/VPA Vidaza 75mg/m2 SC or IV VPA 5mg/kg PO TID Day 1-7 Starting day 1
AML R-113	Vidaza/Mylotarg Vidaza 75mg/m2 SC or IV Mylotarg 3mg/m2 Day 1-7 Day 8
AML R-114	Dacogen Dacogen 20mg/m2 Day 1-5
AML R-115	Vidaza Vidaza 75mg/m2 SC or IV Day 1-5
AML R-116	ATGO Topotecan 1.5mg/m2 CIV Ara-C 2000mg/m2 Mylotarg 4.5mg/m2 Day 1-5 Day 1-5 Day 6
AML R-117	CLAC-MYL Clofarabine 22.5mg/m2 Ara-C 1000mg/m2 Mylotarg 6mg/m2 Day 1-5 Day 1-5 Day 6
AML R-118	Clofarabine Clofarabine 30mg/m2 Day 1-5
AML R-119	Clofarabine/Ara-C Clofarabine 40mg/m2 Ara-C 1000mg/m2 Day 2-6 Day 1-5
AML R-120	CLAG Cladribine 5mg/m2 Ara-C 2000mg/m2 Imatinib 400mg Day 3-7 Day 3-7 BID day 1-15
AML R-121	MEC Mito 6mg/m2 VP-16 80mg/m2 Ara-C 1000mg/m2 Day 1-6 Day 1-6 Day 1-6
AML R-122	Dacogen Dacogen 20mg/m2 (10 day) Day 1-10
AML R-123	Revlimid Revlimid 5-50mg PO daily for 21-28 days every 28 days
AML R-124	Nexavar Nexavar 400mg PO twice daily
AML R-125	Clofarabine/Ara-C Clofarabine 25mg/m2 Ara-C 2000mg/m2 Day 1-5 Day 1-5

Consolidation

#	Regimen
AML C-101	Time Sequential Ara-C 667mg/m2 Ida 12mg/m2 Therapy (TST) Days 1-3, 10-12 Days 1-3
AML C-102	HiDAC Ara-C 3000mg/m2 BID Day 1,3,5
AML C-103	Ara-C Ara-C 400mg/m2 Day 1-5
AML C-104	HiDAC/Dauno Ara-C 3000mg/m2 Dauno 45mg/m2 BID Day 1-6 Day 7-9
AML C-105	Vidaza Vidaza 75mg/m2 SC or IV X 7 days Monday-Friday
AML C-106	Vidaza/VPA Vidaza 75mg/m2 SC or IV VPA 5mg/kg PO TID Day 1-7 Starting day 1
AML C-107	Dacogen Dacogen 20mg/m2 Day 1-5
AML C-108	FLAG Flu 25mg/m2 Ara-C 2000mg/m2 Neupogen 5mcg/kg SC starting Day 1-5 Day 1-5 Day 0 until count recovery
AML C-109	FLAG-Ida Flu 30mg/m2 Ara-C 2000mg/m2 Ida 10mg/m2 Day 1-5 Day 1-5 Day 1-3 Neupogen 5mcg/kg SC starting Day 0 until count recovery
AML C-110	Vidaza Vidaza 75mg/m2 SC or IV Day 1-5
AML C-111	Mito/VP-16 Mito 10mg/m2 VP-16 100mg/m2 Day 1-5 Day 1-5
AML C-112	ATGO Topotecan 1.5mg/m2 CIV Ara-C 2000mg/m2 Mylotarg 4.5mg/m2 Day 1-5 Day 1-5 Day 6

Maintenance

#	Regimen
AML M-101	SC Ara-C Ara-C 10mg/m2 SC BID Day 1-14
AML M-102	Vidaza Vidaza 75mg/m2 SC or IV X 7 days Monday-Friday
AML M-103	Vidaza/VPA Vidaza 75mg/m2 SC or IV VPA 5mg/kg PO TID Day 1-7 Starting day 1
AML M-104	Dacogen Dacogen 20mg/m2 Day 1-5
AML M-105	Vidaza Vidaza 75mg/m2 SC or IV Day 1-5
AML M-106	Revlimid Revlimid 5-50mg PO daily for 21-28 days every 28 days
AML M-107	Nexavar Nexavar 400mg PO twice daily

APL
Induction

#	Regimen
APL I-101	ATRA/ ATRA 22.5mg/m2 Daunorubicin 60mg/m2 Daunorubicin BID PO Day 1-60 Day 4,6,8 (NSH 750)
APL I-102	ATRA/ATO ATRA 22.5mg/m2 Arsenic 0.15 mg/kg/day BID PO Day 1-CR or Day 85 Day 10-CR or Day 85
APL I-103	ATRA/ATO/ ATRA 22.5mg/m2 Arsenic 0.15 mg/kg/day Gemtuzumab BID PO Day 1-CR or Day 85 Day 10-CR or Day 85 Gemtuzumab 9mg/m2 Day 1

Refractory/Relapse/Reinduction

#	Regimen
APL R-101	Arsenic 1 Arsenic 0.15mg/kg/d M-F X 25 doses
APL R-102	Arsenic 2 Arsenic 0.15mg/kg/d Days 1-30

Consolidation

#	Regimen
APL C-101	Arsenic Arsenic 0.15mg/kg M-F X 25 doses
APL C-102	Ara-C/ Ara-C 667mg/m2/d Daunorubicin 60mg/m2/d Arsenic 0.15mg/kg/d starting Daunorubicin/ Day 1-3 Day 1-3 Day 8 M-F x 30 doses Arsenic (NSH 750) (Module II)
APL C-103	Arsenic Arsenic 0.15mg/kg/d (Module III) M-F x 30 doses
APL C-104	ATRA/ATO ATRA 22.5mg/m2 Arsenic 0.15 mg/kg/day BID PO Weeks 1-2 IV M-F Weeks 1-4, 9-12, 17-20, 5-6, 9-10, 13-14, 17-18 25-28 21-22, 25-26
APL C-106	ATRA/ ATRA 22.5mg/m2 Gemtuzumab 9mg/m2 Gemtuzumab BID PO Weeks 1-2 Monthly until 28 weeks post CR 5-6, 9-10, 13-14, 17-18 21-22, 25-26
APL C-107	ATO/ Arsenic 0.15 mg/kg/day Gemtuzumab 9mg/m2 Gemtuzumab IV M-F Weeks 1-4, 9-12, Monthly until 28 weeks post CR 17-20, 25-28
APL C-108	Arsenic Arsenic 10mg IV daily x 4 weeks (fixed dose)

Maintenance

#	Regimen
APL M-101	ATRA ATRA 22.5mg/m2 BID (For 2 years) Day 1-15 q3months
APL M-102	ATRA/6MP/ ATRA 22.5mg/m2 BID 6MP 90mg/m2 PO MTX 15mg/m2 MTX (For 2 years) PO Day 1-15 q3months PO Q24 qweek
APL M-103	Arsenic Arsenic 10mg IV M-F x 10 doses (fixed dose) monthly x 6 months

MDS

#	Regimen
MDS-101	Vidaza Vidaza 75mg/m2 SC or IV X 7 days Monday-Friday
MDS-102	Vidaza/VPA Vidaza 75mg/m2 SC or IV VPA 5mg/kg TID PO Day 1-7 Starting day 1
MDS-103	Dacogen Dacogen 20mg/m2 Day 1-5
MDS-104	FLAG Flu 25mg/m2 Ara-C 2000mg/m2 Neupogen 5mcg/kg SC starting Day 1-5 Day 1-5 Day 0 until count recovery
MDS-105	Vidaza Vidaza 75mg/m2 SC or IV Day 1-5
MDS-106	Revlimid Revlimid 10mg PO daily

CLL:

	Regimen
CLL-101	Campath Campath 3mg Day 1 SC 10mg Day 2, 30mg 3 days/week x 4 weeks beginning Day 3
CLL-102	FCR (flu/cy/ Rituximab 375mg/m2 Cyclophosphamide 250mg/m2 Fludarabine 25mg/m2 rituxan) course1 Day 1 Day 2-4 Day 2-4
CLL-103	FCR (flu/cy/ Rituximab 500mg/m2 Cyclophosphamide 250mg/m2 Fludarabine 25mg/m2 rituxan) course2-6 Day 1 Day 1-3 Day 1-3
CLL - 104	(OFAR ) Oxaliplatin/Fludarabine/Cytarabine/Rituxan Oxaliplatin 25mg/m2 Fludarabine 30mg /m2 Cytarabine 1000mg/m2 Rituxan 375mg/m2 Day 1-4 Day 2-3 Day 2-3 Day 3 cycle 1, day 1 future cycles
CLL - 105	Ofatumumab Ofatumumab 300mg IV once then 2000mg IV weekly x 7 doses then 2000mg IV monthly x 4 doses

ALL: No NCCN guideline available for Acute lymphblastic leukemia. Unfilled regimens are for Acute lymphoblastic lymphoma and T-cell leukemia/lymphoma
Induction

#	Regimen
ALL I-101	CCG1961 Prednisone 20mg/m2 TID Vincristine 2mg Daunorubicin 25mg/m2 (ARM C) PO Day 1-28 then Day 1,8,15,22 Day 1,8,15,22 10 day taper PEG 2500units/m2 IM IT Ara-C 70mg IT MTX 12mg Day 4 Day1 Day 8,29 (Day15,22 if CNS +)
ALL I-102	HyperCVAD Cy 300mg/m2 Vincristine 2mg Doxorubicin 50mg/m2 (1A) BID Day1-3 Day 4,11 Day 4 Dexamethasone 40mg IT Ara-C 100mg IT MTX 12mg PO Day 1-4, 11-14 Day 8 Day 2
ALL I-103	Larson Cy 1200mg/m2 Daunorubicin 45mg/m2 Vincristine 2mg (Age<60) Day 1 Day1-3 Day 1,8,15,22 Prednisone 60mg/m2 L-asparginase 6,000units/m2 IT MTX 12mg PO Daily Day 1-21 IM Day 5,8,11,15,18,22 Day 1
ALL I-104	Larson Cy 800mg/m2 Daunorubicin 30mg/m2 Vincristine 2mg (Age>60) Day 1 Day1-3 Day 1,8,15,22 Prednisone 60mg/m2 L-asparginase 6,000units/m2 IT MTX 12mg PO Daily Day 1-7 IM Day 5,8,11,15,18,22 Day 1
ALL I-105	HyperCVAD Cy 300mg/m2 Vincristine 2mg Doxorubicin 50mg/m2 + Gleevec (1A) BID Day1-3 Day 4,11 Day 4 Dexamethasone 40mg IT Ara-C 100mg IT MTX 12mg PO Day 1-4, 11-14 Day 8 Day 2 Gleevec 600mg PO days 1 -14
ALL I-106	HyperCVAD Cy 300mg/m2 Vincristine 2mg Doxorubicin 50mg/m2 +Rituximab (1A) BID Day1-3 Day 4,11 Day 4 Dexamethasone 40mg IT Ara-C 100mg IT MTX 12mg PO Day 1-4, 11-14 Day 8 Day 2 Rituximab 375mg/m2 Day 1,11
ALL I-107	HyperCVAD Cy 300mg/m2 Vincristine 2mg Doxorubicin 50mg/m2 + Sprycel (1A) BID Day1-3 Day 4,11 Day 4 Dexamethasone 40mg IT Ara-C 100mg IT MTX 12mg PO Day 1-4, 11-14 Day 8 Day 2 Sprycel 100mg PO days 1 -14
ALL I-108	HyperCVAD Cy 300mg/m2 Vincristine 2mg Doxorubicin 50mg/m2 +Pegaspargase BID Day1-3 Day 4,11 Day 4 (1A) Dexamethasone 40mg IT Ara-C 100mg IT MTX 12mg PO Day 1-4, 11-14 Day 8 Day 2 Pegaspargase 2,500units/m2 Day 4

Relapse/Refractory/Reinduction

#	Regimen
ALL R-101	FLAG-Ida Flu 30mg/m2 Ara-C 2000mg/m2 Ida 10mg/m2 Day 1-5 Day 1-5 Day 1-3 Neupogen 5mcg/kg SC starting Day 0 until count recovery
ALL R-102	FLAG-Ida Flu 25mg/m2 Ara-C 2000mg/m2 Ida 12mg/m2 Mylotarg Day 2-6 Day 2-6 Day 4-6 Mylotarg 3mg/m2 Neupogen 5mcg/kg SC starting Day 1 Day +1 until count recovery
ALL R-103	HAM Ara-C 3000mg/m2 Mito 10mg/m2 (6 day) BID Day 1-4 Day 2-6
ALL R-104	HAM Ara-C 3000mg/m2 Mito 10mg/m2 (5 day) BID Day 1-4 Day 2-5
ALL R-105	Nelarabine Nelarabine 1.5gm/m2 (T-cell) Day 1,3,5
ALL R-106	Campath Campath 3mg SC Day 1, 10mg Day 2, 30mg 3 days/week x 4 weeks starting Day 3
ALL R-107	FLAG Flu 25mg/m2 Ara-C 2000mg/m2 Neupogen 5mcg/kg SC starting Day 1-5 Day 1-5 Day 0 until count recovery
ALL R-108	Clofarabine/ Clofarabine 40mg/m2 Cyclophosphamide 200mg/m2 Cytoxan Day 2-4 x1 on Day 1, then Q12h Day 2-4

Consolidation

#	Regimen
ALL C-101	CCG1961 Cy 1000mg/m2 Vincristine 2mg Ara-C 75mg/m2 (ARM C) Day 1,29 Day 15,22,43,50 Day2-5,9-12,30-33,37-40 PEG 2500units/m2 IM 6MP 60mg/m2 PO IT MTX 12mg Day 15,43 Day1-14, 29-42 Day 1,8,15,22 Prednisone tapering from induction
ALL C-102	Hyper CVAD MTX 200mg/m2 MTX 800mg/m2 Ara-C 3000mg/m2 (1B, 2B, 3B, 4B) Day 1 Day 1 over 24 hrs BID Day 2-3 Solu-Medrol 50mg IT Ara-C 100mg IT MTX 12mg Day 1-3 Day 8 (cycle 1B,2B) Day 2 (cycle 1B,2B)
ALL C-103	HyperCVAD Cy 300mg/m2 Vincristine 2mg Doxorubicin 50mg/m2 (2A,3A,4A) BID Day1-3 Day 4,11 Day 4 Dexamethasone 40mg IT Ara-C 100mg IT MTX 12mg PO Day 1-4, 11-14 Day 8 (cycle 2A) Day 2 (cycle 2A)
ALL C-104	Larson Cy 1000mg/m2 6MP 60mg/m2 PO Ara-C 75mg/m2 SC (early intensification Day 1 Day 1-14 Day 1-4,8-11 X 2 cycles) Vincristine 2mg L-asparginase 6,000units/m2 IT MTX 12mg Day 15,22 IM Day 15,18,22,25 Day 1
ALL C-105	POG-9906 Cy 1000mg/m2 Vincristine 2mg Ara-C 75mg/m2 SC Day 29 Day 43,50 Day 30-33,37-40 L-asparginase IM 6MP 60mg/m2 PO IT MTX 12mg 6,000units/m2 Day 29-42 Day 29,43 Day 43,45,47,50,52,54
ALL C-106	Linker Daunorubicin 50mg/m2 Vincristine 2mg Prednisone 60mg/m2 PO Consol A Day 1,2 Day 1,8 Divided TID Day 1-14 L-asparginase 12,000 units/m2 IM Day 2,4,7,9,11,14
ALL C-107	HyperCVAD Cy 300mg/m2 Vincristine 2mg Doxorubicin 50mg/m2 + Gleevec BID Day1-3 Day 4,11 Day 4 (2A,3A, 4A) Dexamethasone 40mg IT Ara-C 100mg IT MTX 12mg PO Day 1-4, 11-14 Day 8 Day 2 Gleevec 600mg PO daily (cycle 2A only) (cycle 2A only)
ALL C-108	Hyper CVAD MTX 200mg/m2 MTX 800mg/m2 Ara-C 3000mg/m2 + Gleevec Day 1 Day 1 over 24 hrs BID Day 2-3 (1B, 2B, 3B, 4B) Solu-Medrol 50mg IT Ara-C 100mg IT MTX 12mg Day 1-3 Day 8 (cycle 1B,2B) Day 2 (cycle 1B,2B) Gleevec 600mg daily
ALL C-109	Hyper CVAD MTX 200mg/m2 MTX 800mg/m2 Ara-C 3000mg/m2 +Rituximab Day 1 Day 1 over 24 hrs BID Day 2-3 (1B, 2B, 3B, 4B) Solu-Medrol 50mg IT Ara-C 100mg IT MTX 12mg Day 1-3 Day 8 (cycle 1B,2B) Day 2 (cycle 1B,2B) Rituximab 375mg/m2 Day 1 and 8 (cycle 1B and 2B only)
ALL C-110	HyperCVAD Cy 300mg/m2 Vincristine 2mg Doxorubicin 50mg/m2 +Rituximab BID Day1-3 Day 4,11 Day 4 (2A, 3A, 4A) Dexamethasone 40mg IT Ara-C 100mg IT MTX 12mg PO Day 1-4, 11-14 Day 8 (cycle 2A) Day 2 (cycle 2A) Rituximab 375mg/m2 Day 1,11 (cycle 2A only)
ALL C-111	HyperCVAD Cy 300mg/m2 Vincristine 2mg Doxorubicin 50mg/m2 + Sprycel BID Day1-3 Day 4,11 Day 4 (2A,3A, 4A) Dexamethasone 40mg IT Ara-C 100mg IT MTX 12mg PO Day 1-4, 11-14 Day 8 Day 2 Sprycel 100mg PO daily day 1-14
ALL C-112	Hyper CVAD MTX 200mg/m2 MTX 800mg/m2 Ara-C 3000mg/m2 + Sprycel Day 1 Day 1 over 24 hrs BID Day 2-3 (1B, 2B, 3B, 4B) Solu-Medrol 50mg IT Ara-C 100mg IT MTX 12mg Day 1-3 Day 8 (cycle 1B,2B) Day 2 (cycle 1B,2B) Sprycel 100mg PO daily day 1-14
ALL C-113	HyperCVAD Cy 300mg/m2 Vincristine 2mg Doxorubicin 50mg/m2 +Pegaspargase BID Day1-3 Day 4,11 Day 4 (2A, 3A, 4A) Dexamethasone 40mg IT Ara-C 100mg IT MTX 12mg PO Day 1-4, 11-14 Day 8 (cycle 2A) Day 2 (cycle 2A) Pegaspargase 2,500units/m2 Day 4 (cycle 2A only)

Interim Maintenance

#	Regimen
ALL IM-101	CCG1961 Vincristine 2mg MTX 100mg/m2 IT MTX12mg (ARM C) Day 1,11,21,31,41 and escalated to max 300mg/m2 Day1, 31 PEG 2500units/m2 Day1,11,21,31,41 IM Day 2,22
ALL IM-102	POG-9906 Vincristine 2mg MTX 100mg/m2 IT MTX 12mg Day 1,11,21,31,41 and escalated to max 300mg/m2 Day1, 31 L-asparginase IM Day1,11,21,31,41 15000units/m2 Day 2,12,22,32,42

Intensification

#	Regimen
ALL IN-101	CCG1961 Dexamethasone 10mg/m2 Vincristine 2mg Doxorubicin 25mg/m2 (ARM C) Day 1-21 PO Day 1,8,15 Day 1,8,15 Reinduction PEG 2500units/m2 IM IT MTX 12mg Day 4 Day1
ALL IN-102	CCG1961 Cy 1000mg/m2 Vincristine 2mg Ara-C 75mg/m2 (ARM C) Day 1 Day 15,22 Day2-5,9-12 Reconsolidation PEG 2500units/m2 IM 6TG 60mg/m2 IT MTX 12mg Day 15 Day1-14 Day 1,8
ALL IN-103	HyperCVAD MTX 100mg/m2 L-asparginase 20,000units Day 1,8,15,22 IM Day 2,9,16,23
ALL IN-104	POG-9906 Vincristine 2mg Dexamethasone 5mg/m2 Doxorubicin 25mg/m2 Reinduction Day 57,64,71 PO BID Day 57-63,71-77 Day 57,64,71 L-asparginase IM IT MTX12mg 6000 units/m2 Day 60,62,64,67,69,71 Day 57
ALL IN-105	POG-9906 Cy 1000mg/m2 Vincristine 2mg Ara-C 75mg/m2 SC Reconsolidation Day 85 Day 99,106 Day 86-89,93-96 L-asparginase 6TG 60mg/m2 PO IT MTX 12mg IM 6000mg/m2 Day 85-98 Day 85 Day 99,101,103,106,108,110
ALL IN-106	HyperCVAD Cy 300mg/m2 Vincristine 2mg Doxorubicin 50mg/m2 +Rituximab BID Day1-3 Day 4,11 Day 4 Dexamethasone 40mg Rituximab 375mg/m2 PO Day 1-4, 11-14 Day 1,11

Maintenance

#	Regimen
ALL M-101	CCG1961 Prednisone 40mg/m2 Vincristine 2mg 6MP 75mg/m2 PO (ARM C) PO Day 1-5,29-33,57-61 Day 1,29,57 Day 1-84 PO MTX 20mg/m2 IT MTX 12mg Day 8,15,22,29,36,43,50,57,64,71,78 Day 1, 29(1st 4 courses)
ALL M-102	HyperCVAD 6MP 50mg TID PO PO MTX 20mg/m2 Vincristine 2mg (POMP) x 2 - 2.5 years qweek x 2 - 2.5 years qmonth x 2 - 2.5 years Prednisone 200mg x 5 days qmonth x 2 – 2.5years
ALL M-103	NCI-CCSG 6MP 75mg/m2 PO PO MTX 20mg/m2 Vincristine 2mg (12 cycles) divided TID x 4 weeks qweek x 4 weeks Day 1 q5weeks Beginning day 1 week 2 Beginning day 1 week 2 Beginning day 1 week 1 Dexamethasone 6mg/m2 TID PO x 5 days q5weeks Beginning day 1 week 1
ALL M-104	POG-9906 Vincristine 2mg Dexamethasone 6mg/m2 6MP 75mg/m2 (continuation) Day 1 PO Divided BID Day 1-5 PO Day 1-28 (q28 days ) PO MTX 20mg/m2 IT MTX 12mg Day 1,8,15,22 Day 1 of month 1 only

HCL: no NCCN guideline available

#	Regimen
HCL-101	Cladribine Cladribine 0.12mg/kg Day 1-5

Aplastic Anemia: no NCCN guideline available

#	Regimen
AA-101	ATG+CSA Equine ATGAM 40mg/kg CSA 6mg/kg BID PO Day 1-4 x 6 months

NHL

#	Regimen
NHL-101	Cy/Vincristine Cy 500mg/m2 Vincristine 2mg MTX 150mg/kg MTX/VP-16/ Day 0,1 Day 0,35 Day 7 Doxorubicin VP-16 250mg/m2 BID MTX 250mg/kg Doxorubicin 50mg/m2 (Burkitts) Day 14 Day 21 Day 28 IT MTX IT Ara-C Day 6,20,34 Day 13,27,41
NHL-102	MaGrath Cy 800mg/m2 Cy 200mg/m2 Doxorubicin 40mg/m2 Regimen A Day 1 Day 2-5 Day 1 (CODOX-M Vincristine 2mg MTX 1200mg/m2 MTX 5520mg/m2 Burkitts) Day 1,8 (1,8,15 on Day 10 Day 10 Cycle 3) IT MTX IT Ara-C Day 15 Day 1,3
NHL-103	HyperCVAD+ Cy 300mg/m2 Vincristine 2mg Doxorubicin 50mg/m2 Rituxan A BID Day1-3 Day 4,11 Day 4 (Burkitts) Dexamethasone 40mg IT Ara-C IT MTX PO Day 1-4, 11-14 Day 8 Day 2 Rituxan 375mg/m2 Day 1,11 (1A and 2A only)
NHL-104	Hyper CVAD+ MTX 200mg/m2 MTX 800mg/m2 Ara-C 3000mg/m2 Rituxan B Day 1 Day 1 over 24 hrs BID Day 2-3 (Burkitts) Rituxan 375mg/m2 IT Ara-C IT MTX Day 1,8 (1B and 2B only) Day 8 Day 2
NHL-105	Hyper CVAD+ Cy 300mg/m2 Vincristine 2mg Doxorubicin 50mg/m2 Rituxan BID Day1-3 Day 4,11 Day 4 Consolidaton A Dexamethasone 40mg Rituxan 375mg/m2 (Mantle cell) Day 1-4, 11-14 Day 1,11(1A and 2A only)
NHL-106	ICE VP-16 100mg/m2 Carboplatin AUC 5 Ifosfomide 5000mg/m2 Day 1-3 Day 2 Day 2
NHL-107	Mini-ICE Ifosfomide 1000mg/m2 VP-16 150mg/m2 Carboplatin 200mg/m2 Day 1-2 BID Day 1-2 Day 1-2
NHL-108	RICE VP-16 100mg/m2 Carboplatin AUC 5 Ifosfomide 5000mg/m2 Day 1-3 Day 2 Day 2 Rituxan 375mg/m2 Day 1
NHL-109	RCHOP Cy 750mg/m2 Doxorubicin 50mg/m2 Vincristine 2mg Day 1 Day 1 Day 1 Prednisone 100mg Rituxan 375mg/m2 PO Day 1-5 Day 1
NHL-110	Rituxan/ Rituxan 375mg/m2 Gemcitabine 1000mg/m2 Oxaliplatin 100mg/m2 Gemcitabine/ Day 1 Day 2 Day 2 Oxaliplatin
NHL-111	Rituxan Rituxan 375mg/m2 Once weekly x 4
NHL-112	High dose Rituxan 1000mg/m2 Rituxan Once weekly x 4
NHL-113	ESHAP VP-16 40mg/m2 Methylprednisolone 500mg Cisplatin 25mg/m2 Day 1-4 Day 1-5 Day 1-4 Cytarabine 2000mg/m2 Day 5
NHL-114	Hyper CVAD+ MTX 200mg/m2 MTX 800mg/m2 Ara-C 3000mg/m2 Rituxan B Day 1 Day 1 over 24 hrs BID Day 2-3 (Mantle Cell) Rituxan 375mg/m2 Day 1, 8(1B and 2B only)
NHL-115	Bendamutine+ Bendamustine 90mg/m2 Rituxan 375mg/m2 Rituxan Day 2-3 Day 1
NHL-116	DA-REPOCH Etoposide 50mg/m2 Doxorubicin 10mg/m2 Vincristine 0.4mg/m2 In HIV Day 1-4 Day 1-4 Day 1-4 Cyclophosphamide 187mg/m2 – 750mg/m2 Prednisone 60mg/m2 Day 5 BID Day 1-5 Rituxan 375mg/m2 Day1
NHL-117	REPOCH Etoposide 50mg/m2 Doxorubicin 10mg/m2 Vincristine 0.4mg/m2 Day 1-4 Day 1-4 Day 1-4 Cyclophosphamide 750mg/m2 Prednisone 60mg/m2 Day 5 Day 1-5 Rituxan 375mg/m2 Day1

T-Cell Lymphoma

#	Regimen
TCL-101	Denileukin Denileukin diftitox 18mcg/kg/day diftitox Day 1-5

T/LL
Consolidation

#	Regimen
T/LL C-101	Hoelzer Ara-C 1000mg/m2 Mitoxantrone 10mg/m2 Consolidation #1 BID Day 1-4 Day 3-5 Course #1
T/LL C-102	Hoelzer MTX 1500mg/m2 L-asparaginase 6MP 25mg/m2 PO Consolidation #1 Day 1,15 10,000 units/m2 Day 2,16 Day 1-5,15-19 Course #2
T/LL C-103	Hoelzer VP-16 100mg/m2 Ara-C 150mg/m2 Consolidation #2 Day 1-5 Day 1-5 Cycle A
T/LL C-104	Hoelzer Cy 1000mg/m2 Ara-C 500mg/m2 Consolidation #2 Day 1 Day 1 Cycle B

Reinduction

#	Regimen
T/LL R-101	Hoelzer Prednisone 60mg/m2 Vincristine 2mg Doxorubicin 25mg/m2 Reinduction PO Day 1-28 Day 1,8,15,22 Day 1,8,15,22 Course #1 IT MTX/Ara-C Day 1
T/LL R-102	Hoelzer Cy 1000mg/m2 Ara-C 75mg/m2 6-TG 60mg/m2 PO Reinduction Day 1 Day 3-6,10-13 Day 1-14 Course #2 IT MTX/Ara-C Day 1

#	Regimen
HD-101	Gemcitabine/ Gemcitabine 1000mg/m2 Cisplatin 75mg/m2 Dexamethasone 40mg Dexamethasone/ Day 1,8 Day 1 PO Day 1-4 Cisplatin
HD-102	ICE VP-16 100mg/m2 Carboplatin AUC 5 Ifosfomide 5000mg/m2 Day 1-3 Day 2 Day 2
HD-103	GVD Gemcitibine 1000mg/m2 Vinorelbine 20mg/m2 Liposomal doxorubicin 15mg/m2 (Gemcitibine/ Day 1,8 Day1,8 Day 1,8 Vinorelbine/Doxil)
HD-104	GVD Gemcitibine 800mg/m2 Vinorelbine 15mg/m2 Liposomal doxorubicin 10mg/m2 (Gemcitibine/ Day 1,8 Day1,8 Day 1,8 Vinorelbine/Doxil) (Post-transplant)
HD-105	GV Gemcitibine 1000mg/m2 Vinorelbine 25mg/m2 (Gemcitibine/ Day 1,8 Day 1,8 Vinorelbine)
HD-106	Mini BEAM BCNU 60mg/m2 Ara-C 100mg/m2 VP16 75mg/m2 Day 1 Q12hrs Day 2-5 Day 2-5 Melphalan 30mg/m2 Day 6
HD-107	Bendamustine Bendamustine 120mg/m2 Day 1-2
HD-108	Brentuximab Brentuximab 1.8mg/kg Day 1 (21 day cycle)

#	Regimen
MM-101	DT-PACE Thalidomide 400mg Dexamethasone 40mg Cisplatin 10mg/m2 Daily PO PO Day 1-4 Day 1-4 Cy 400mg/m2 VP-16 40mg/m2 Doxorubicin 10mg/m2 Day 1-4 Day 1-4 Day 1-4
MM-102	Melphalan Mel 50mg/m2 (intermediate dose) Day 1
MM-103	Velcade Velcade 1.3mg.m2 Day 1,4,8,11
MM-104	Velcade/ Velcade 1.3mg.m2 Dexamethasone 20mg PO Dexamethasone Day 1,4,8,11 Day 1,2,4,5,8,9,11,12
MM-105	Rev/Vel/Dex Revlimid 25mg daily Velcade 1.3mg/m2 Dexamethasone 40mg PO Day 1-14 PO Day 1,4,8,11 Day 1,2,4,5,8,9,11,12 cycle 1-4 Dexamethasone 20mg PO Day 1,2,4,5,8,9,11,12 cycle 5-8
MM-106	MAC Melphalan 0.1mg/kg PO Arsenic 0.25mg/kg IV (mel/arsenic/ Day 1-4 of each 6 week Cycle 1 Day 1through 4,7,10,14,17,21,24,28,31 ascorbic acid) cycle Cycle 2-6 Day 1,4,7,10,14,17,21,24,28,31 Ascorbic acid 1gm IV +- Prednisone 100mg PO Cycle 1 Day 1through4,7,10,14,17,21,24,28,31 Days 1-4 and 22-25. If patient Cycle 2-6 Day 1,4,7,10,14,17,21,24,28,31 has progressive disease.
MM-107	Velcade/Doxil Velcade 1.3mg.m2 Doxil 30mg/m2 Day 1,4,8,11 Day 4
MM-108	Bendamustine/ Bendamustine 60mg/m2 Thalidomide 200mg daily Prednisone 100mg daily Thal/Pred Days 1,8,15 every 28 days Days 1-28 Days 1, 8, 15, 22
MM-109	DVd Liposomal doxorubicin 40mg/m2 Vincristine 2mg Dexamethasone 40mg Day 1 Day 1 Day 1-4

PCL

#	Regimen
PCL-101	Cy/ Cy 750mg/m2 Dexamethasone 40mg/m2 Velcade 1.3mg/m2 Dexamthasone/ Day 1,3 Divided BID Day 1-4 Day 1,4,8,11 Velcade
PCL-102	Cy/ Cy 4000mg/m2 Dexamethasone 40mg/m2 Velcade 1.3mg/m2 Dexamthasone/ Day 1 Divided BID Day 1-4 Day 1,4,8,11 Velcade

Tyrosine Kinase Inhibitors

#	Regimen
TYRO-101	Imatinib Imatinib 200mg – 800mg daily (may be given in divided doses)
TYRO-102	Dasatinib Dasatinib 20mg – 200mg daily (may be given in divided dose)
TYRO-103	Nilotinib Nilotinib 400mg – 800mg daily (may be given in divided dose)

Intrathecal

#	Regimen
INTR-101	Ara-C Ara-C 100mg IT
INTR-102	Depocyt Depocyt 50mg IT
INTR-103	MTX MTX 12mg IT

Miscellaneous

#	Regimen
MISC-101	VeIP Vinblastine 0.11mg/kg Ifosfamide 1200mg/m2 Cisplatin 20mg/m2 Day 1-2 Day 1-5 Day 1-5
MISC-102	TIP Paclitaxel 250mg/m2 Ifosfamide 1500mg/m2 Cisplatin 25mg/m2 Day 1 Day 2-5 Day 2-5
MISC-103	CE Cisplatin 60mg/m2 VP16 120mg/m2 Day 1 Day 1-3

Modified

#	Regimen
MOD-101	Modified regimen